EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention
Gibson CM, Giugliano RP, Kloner RA, et al. European Heart Journal 2016;37:1296-1303.
What it found
In people having a first anterior heart attack treated with stenting, the drug (then called MTP-131) did not reduce heart muscle damage compared with placebo, and imaging and clinical outcomes did not improve. It was well tolerated.
Limitations
Negative trial for its main goal. Single dose.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.